Pfizer is co-developing and co-commercializing a portfolio of 12 cancer medicines, creating significant R&D and commercialization activity.
Filing excerpt
In May 2026, we entered into a strategic global licensing and collaboration agreement with Innovent, a Chinese biopharmaceutical company, for the research and development of 12 early-stage and de novo cancer medicines.
What this signalsFilings often name leadership changes, deals and spending plans.
Technologies
Vendors
Regions named
sec-10qjointVentureGet every 10-Q signal for Pfizer and the companies you sell to, in the tools you already use.
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Pfizer this week?”
The Signal API returns 10-Q signals for any list of companies as JSON, for your CRM, warehouse or app.
Sign up and spend your free credits on the companies you sell to.
This page shows a preview. The full sec-10q record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the APISignal
signal_nameValue in the APIassociationValue in the APIGET /v1/signals/cbba6405-ffe5-468f-b062-e369139521c1 returns this record as JSON. POST /v1/companies/enrich returns every signal for pfizer.com.
{
"signal_id": "cbba6405-ffe5-468f-b062-e369139521c1",
"signal_type": "sec-10q",
"signal_subtype": "jointVenture",
"detected_at": "2026-08-11T08:09:10.36+00:00",
"company": {
"name": "Pfizer",
"domain": "pfizer.com"
},
"data": {
"detail": "Pfizer is co-developing and co-commercializing a portfolio of 12 cancer medicines, creating significant R&D and commercialization activity. This presents opportunities for vendors supporting clinical trials, regulatory affairs, and go-to-market for antibody-drug conjugates (ADCs).",
"metrics": {
"timeframe": "current_year",
"dollar_context": "Total potential value of collaboration agreement with Innovent, including $650M upfront and $9.85B in milestones.",
"dollar_millions": 10500
},
"summary": "Pfizer forms $10.5B oncology JV with Innovent for 12 new cancer drugs",
"excerpts": "In May 2026, we entered into a strategic global licensing and collaboration agreement with Innovent, a Chinese biopharmaceutical company, for the research and development of 12 early-stage and de novo cancer medicines.",
"relevance": 0.9,
"sentiment": "positive",
"confidence": "high",
"source_url": "https://www.sec.gov/Archives/edgar/data/78003/000007800326000095/pfe-20260628.htm",
"filing_date": "2026-08-04",
"filing_year": 2026,
"fiscal_year": 0,
"fiscal_year_end": "06/28",
"sales_relevance": "New entity needs",
"signal_category": "strategic",
"regions_mentioned": [
"U.S.",
"U.K.",
"European Union"
],
"vendors_mentioned": [
"Innovent"
],
"technologies_mentioned": [
"antibody-drug conjugates (ADCs)",
"multi-specific antibodies"
]
}
}
curl https://signals.autobound.ai/v1/signals/cbba6405-ffe5-468f-b062-e369139521c1 \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"pfizer.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.